Skip to main content

Table 1 Population Characteristics

From: Prognostic utility of differential tissue characterization of cardiac neoplasm and thrombus via late gadolinium enhancement cardiovascular magnetic resonance among patients with advanced systemic cancer

 

Overall

(n = 126)

CMASS +

(n = 63)

CMASS -

(n = 63)

p

CMASS +

p

CNEO

(n = 40)

CTHR

(n = 23)

Clinical Characteristics

 Age (years)

57 ± 15

57 ± 15

56 ± 16

0.58

60 ± 14

53 ± 16

0.10

 Male gender

56% (70)

54% (34)

57% (36)

0.85

55% (22)

52% (12)

0.83

 Body Surface Area (m2)

1.8 ± 0.3

1.8 ± 0.3

1.9 ± 0.3

0.49

1.8 ± 0.3

1.8 ± 0.2

0.66

Leading Cancer Etiologiesa

 Gastrointestinal

19% (24)

19% (12)

19% (12)

1.00

15% (6)

26% (6)

0.33

 Sarcoma

16% (20)

16% (10)

16% (10)

1.00

20% (8)

9% (2)

0.30

 Lymphoma

14% (18)

14% (9)

14% (9)

1.00

5% (2)

30% (7)

0.009

 Lung

14% (18)

14% (9)

14% (9)

1.00

18% (7)

9% (2)

0.47

 Genitourinary

13% (16)

13% (8)

13% (8)

1.00

13% (5)

13% (3)

1.00

Cancer Stage

  I - III

5% (6)

5% (3)

5% (3)

1.00

0%

13% (3)

0.045

  IV

95% (120)

95% (60)

95% (60)

1.00

100% (40)

87% (20)

0.045

Disease Extent (# organs involved)

2.7 ± 2.0

3.1 ± 2.1

2.4 ± 1.8

0.02

3.6 ± 2.0

2.3 ± 2.1

0.02

Anti-Cancer Regimen

 Chemotherapy

  Alkylating agent

32% (40)

29% (18)

36% (22)

0.48

31% (12)

26% (6)

0.70

  Platinum

36% (45)

41% (26)

30% (19)

0.25

50% (20)

26% (6)

0.06

  Antimetabolite

37% (47)

40% (25)

35% (22)

0.71

38% (15)

44% (10)

0.64

  Anthracycline

25% (32)

25% (16)

25% (16)

1.00

25% (10)

26% (6)

0.92

  Mitotic inhibitor

37% (47)

37% (23)

38% (24)

1.00

35% (14)

39% (9)

0.74

  Biologic agents

32% (40)

32% (20)

32% (20)

1.00

30% (12)

35% (8)

0.70

  Radiation Therapy

36% (45)

37% (23)

35% (22)

1.00

35% (14)

39% (9)

0.74

Antiplatelet Therapyb

24% (30)

19% (12)

29% (18)

0.31

15% (6)

26% (6)

0.33

Anticoagulation Therapyc

26% (33)

35% (22)

18% (11)

0.04

30% (12)

16% (10)

0.28

Coronary Artery Disease

11% (14)

8% (5)

14% (9)

0.42

5% (2)

13% (3)

0.35

 Atherosclerosis Risk Factors

  Hypertension

35% (44)

32% (20)

38% (24)

0.56

35% (14)

26% (6)

0.46

  Diabetes mellitus

10% (12)

5% (3)

14% (9)

0.15

8% (3)

0% (0)

0.29

  Hypercholesterolemia

26% (33)

21% (13)

32% (20)

0.25

15% (6)

30% (7)

0.20

  Tobacco use

46% (58)

46% (29)

46% (29)

1.00

38% (15)

61% (14)

0.07

Cardiac Morphology and Function

 Left Ventricle

  Ejection fraction (%)

61 ± 12

63 ± 9

59 ± 15

0.09

63 ± 9

62 ± 10

0.51

  Ejection fraction <50%

15% (19)

12% (7)

20% (12)

0.27

11% (4)

13% (3)

1.00

  Stroke volume (mL)

70 ± 24

70 ± 25

70 ± 22

0.98

67 ± 23

74 ± 29

0.31

  End-diastolic volume (mL)

119 ± 45

113 ± 43

125 ± 47

0.18

107 ± 38

122 ± 50

0.19

  End-systolic volume (mL)

49 ± 34

43 ± 23

55 ± 42

0.06

40 ± 20

48 ± 28

0.19

  End-diastolic diameter (cm)

4.7 ± 0.7

4.6 ± 0.7

4.8 ± 0.8

0.08

4.5 ± 0.6

4.8 ± 0.7

0.06

  Myocardial mass (gm)

118 ± 55

121 ± 69

115 ± 37

0.53

126 ± 79

112 ± 51

0.44

 Right Ventricle

  Ejection fraction (%)

53 ± 8

53 ± 9

53 ± 8

0.92

53 ± 9

54 ± 8

0.47

  Ejection fraction <50%

17% (22)

22% (13)

15% (9)

0.45

27% (10)

13% (3)

0.33

  Stroke volume (ml)

69 ± 26

69 ± 26

71 ± 25

0.69

66 ± 23

74 ± 31

0.27

  End-diastolic volume (mL)

134 ± 50

129 ± 47

139 ± 52

0.23

127 ± 43

135 ± 55

0.49

  End-systolic volume (mL)

64 ± 33

61 ± 26

67 ± 38

0.24

61 ± 26

62 ± 27

0.88

 Atria

  Left atrial area (cm2)

20 ± 7

20 ± 7

20 ± 6

0.97

19 ± 7

21 ± 8

0.40

  Right atrial area (cm2)

19 ± 7

19 ± 6

19 ± 7

0.94

19 ± 6

19 ± 6

0.71

  1. aOther cancer etiologies for CNEO: melanoma/skin (13% [n = 5]), endocrine (10% [n = 4]), head/neck (5% [n = 2]), and breast (3% [n = 1])
  2. bAspirin or thienopyridine
  3. cWarfarin, non-vitaming K oral anticoagulant, or full dose low molecular weight heparin
Back to article page

Journal of Cardiovascular Magnetic Resonance

ISSN: 1532-429X

Contact us